Imunon (IMNN) Q2 2024 earnings summary

Executive summary

• Reported positive topline Phase II results for IMNN-001 in advanced ovarian cancer, showing significant survival benefits and supporting advancement to phase III in 2025.

• Advanced IMNN-101, a COVID-19 booster candidate, with first participants dosed in a Phase I trial and topline data expected by year-end 2024.

• Raised $10 million in gross proceeds through a registered direct offering, strengthening the balance sheet and providing short-term liquidity.

• Leadership transition completed with new CEO and interim CFO, and separation of Chief Medical Officer, ensuring continuity and strategic focus.

• The company continues to operate at a net loss, with substantial doubts about its ability to continue as a going concern without additional funding.

Financial highlights

• Net loss for Q2 2024 was $4.8 million ($0.51/share), improved from $5.6 million ($0.61/share) in Q2 2023; H1 2024 net loss was $9.7 million ($1.03/share), down from $11.2 million ($1.28/share) in H1 2023.

• Operating expenses for Q2 2024 were $5.0 million, down 8% year-over-year; R&D expenses were $2.8 million, and G&A expenses were $2.2 million.

• Cash and equivalents were $5.3 million at June 30, 2024, with an additional $9–10 million raised post-quarter, extending runway into Q3 2025.

• Working capital at June 30, 2024 was $2.5 million, down from $10.8 million at year-end 2023.

• Net cash used in operating activities for the first half of 2024 was $10.2 million.

Outlook and guidance

• End-of-phase II FDA meeting for IMNN-001 expected in fall 2024; phase III trial to start Q1 2025, with top-line data targeted for end of 2028.

• Topline data from the IMNN-101 Phase I COVID-19 booster trial expected by year-end 2024, with partnering discussions to follow.

• Ongoing MRD study in ovarian cancer progressing, with enrollment expected to accelerate as new sites join.

• Anticipated phase III trial cost is ~$50 million; current financing provides a bridge to key milestones while additional capital and partnerships are pursued.

• Management expects continued operating losses and negative cash flows, with current cash resources insufficient to fund operations for the next twelve months without further funding.